Bionomics Limited (BNOX)
NASDAQ: BNOX · Real-Time Price · USD
0.197
-0.003 (-1.25%)
At close: Nov 1, 2024, 4:00 PM
0.190
-0.006 (-3.30%)
After-hours: Nov 1, 2024, 7:37 PM EDT

Company Description

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers.

The company’s lead drug candidate includes BNC210, a negative allosteric modulator of the α7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

The company has a collaboration with Merck & Co., Inc. to identify novel α7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder.

Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Bionomics Limited
Bionomics logo
Country Australia
Founded 1996
IPO Date Dec 16, 2021
Industry Biotechnology
Sector Healthcare
Employees 24
CEO Spyridon Papapetropoulos

Contact Details

Address:
200 Greenhill Road
Eastwood, SA 5063
Australia
Phone 61 8 8150 7400
Website bionomics.com.au

Stock Details

Ticker Symbol BNOX
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
IPO Price $15.45
CIK Code 0001191070
CUSIP Number 09063M205
ISIN Number US09063M2052
SIC Code 2834

Key Executives

Name Position
Dr. Spyridon Papapetropoulos M.D., Ph.D. Chief Executive Officer, President and Director
Timothy M. Cunningham CPA, M.B.A. Chief Financial Officer
Elizabeth Doolin Senior Vice President of Clinical Development
Dr. Julie Kerner Ph.D. Senior Vice President of Business Operations
Dr. Mark A. Smith M.D., Ph.D. Chief Medical Officer
Adrian Hinton BEC, F.C.A. Financial Controller

Latest SEC Filings

Date Type Title
Oct 10, 2024 8-K Current Report
Oct 9, 2024 PRE 14A Other preliminary proxy statements
Oct 7, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Oct 2, 2024 8-K Current Report
Sep 30, 2024 10-K Annual Report
Jul 16, 2024 8-K Current Report
Jun 26, 2024 EFFECT Notice of Effectiveness
Jun 26, 2024 424B3 Prospectus
Jun 21, 2024 UPLOAD Filing
Jun 18, 2024 F-1 Registration statement for certain foreign private issuers